anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The current techniques for antithrombotic coating on blood-contacting biomedical materials and devices are usually complex and lack practical feasibility with weak coating stability and low heparin immobilization. Here, a heparinized self-healing polymer coating with inflammation modulation is introduced through thermal-initiated radical copolymerization of methacrylate esterified heparin (MA-heparin) with methyl methacrylate (MMA) and n-butyl acrylate (nBA), followed by the anchoring of reactive oxygen species (ROS)-responsive polyoxalate containing vanillyl alcohol (PVAX) onto the coating through esterification. The aspirin, which is readily dissolved in the solution of MMA and nBA, is encapsulated within the coating after copolymerization. The copolymerization of MA-heparin with MMA and nBA significantly increases the heparin content of the coating, effectively inhibiting thrombosis and rendering the coating self-healing to help maintain long-term stability. ROS-responsive PVAX and aspirin released in a temperature-dependent manner resist acute and chronic inflammation, respectively. The heparinized self-healing and inflammation-modulated polymer coating exhibits the ability to confer long-term stability and hemocompatibility to blood-contacting biomedical materials and devices. STATEMENT OF SIGNIFICANCE: Surface engineering for blood-contacting biomedical devices paves a successful way to reduce thrombotic and inflammatory complications. However, lack of effectiveness, long-term stability and practical feasibility hinders the development and clinical application of existing strategies. Here we design a heparinized self-healing and inflammation-modulated polymer coating, which possesses high heparin level and self-healing capability to maintain long-term stability. The polymer coating is practically feasible to varied substrates and demonstrated to manipulate inflammation and prevent thrombosis both in vitro and in vivo. Our work provides a new method to develop coatings for blood-contacting biomedical materials and devices with long-term stability and hemocompatibility.
The subject population will involve 10 non-pregnant women. The tactile imaging reprifucibility sub-group will include 5 non-pregnant subjects with 2 tactile imaging examinations completed in one session. All other subjects will have a single tactile imaging examination.
Levetiracetam is an antiepileptic drug.

The chemical name of levetiracetam, a single enantiomer, is (-)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formula is C8H14N2O2 and its molecular weight is 170.21. Levetiracetam is chemically unrelated to existing antiepileptic drugs (AEDs). It has the following structural formula:

Levetiracetam, USP is a white crystalline powder freely soluble in methanol.

Each levetiracetam tablet intended for oral administration contains 250 mg or 1000 mg of levetiracetam. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone and sodium starch glycolate.
BACKGROUND: There is a growing population of survivors of colorectal cancer (CRC). Fatigue and insomnia are common symptoms after CRC, negatively influencing health-related quality of life (HRQoL). Besides increasing physical activity and decreasing sedentary behavior, the timing and patterns of physical activity and rest over the 24-h day (i.e. diurnal rest-activity rhythms) could also play a role in alleviating these symptoms and improving HRQoL. We investigated longitudinal associations of the diurnal rest-activity rhythm (RAR) with fatigue, insomnia, and HRQoL in survivors of CRC.
METHODS: In a prospective cohort study among survivors of stage I-III CRC, 5 repeated measurements were performed from 6 weeks up to 5 years post-treatment. Parameters of RAR, including mesor, amplitude, acrophase, circadian quotient, dichotomy index, and 24-h autocorrelation coefficient, were assessed by a custom MATLAB program using data from tri-axial accelerometers worn on the upper thigh for 7 consecutive days. Fatigue, insomnia, and HRQoL were measured by validated questionnaires. Confounder-adjusted linear mixed models were applied to analyze longitudinal associations of RAR with fatigue, insomnia, and HRQoL from 6 weeks until 5 years post-treatment. Additionally, intra-individual and inter-individual associations over time were separated.
RESULTS: Data were available from 289 survivors of CRC. All RAR parameters except for 24-h autocorrelation increased from 6 weeks to 6 months post-treatment, after which they remained relatively stable. A higher mesor, amplitude, circadian quotient, dichotomy index, and 24-h autocorrelation were statistically significantly associated with less fatigue and better HRQoL over time. A higher amplitude and circadian quotient were associated with lower insomnia. Most of these associations appeared driven by both within-person changes over time and between-person differences in RAR parameters. No significant associations were observed for acrophase.
CONCLUSIONS: In the first five years after CRC treatment, adhering to a generally more active (mesor) and consistent (24-h autocorrelation) RAR, with a pronounced peak activity (amplitude) and a marked difference between daytime and nighttime activity (dichotomy index) was found to be associated with lower fatigue, lower insomnia, and a better HRQoL. Future intervention studies are needed to investigate if restoring RAR among survivors of CRC could help to alleviate symptoms of fatigue and insomnia while enhancing their HRQoL.
TRIAL REGISTRATION: EnCoRe study NL6904 ( https://www.onderzoekmetmensen.nl/ ).
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology. A parvovirus capsid protein is presented containing an amino acid sequence of a capsid protein derived from the serotype of an adeno-associated virus (AAV) or any other parvovirus with an icosahedral capsid structure T=1, while the variable region loop 1 (VR1) containing the amino acid residues 258-272 of the AAV1 capsid protein or the corresponding amino acid residues of another AAV or parvoviral capsid protein is modified by deleting and/or replacing one or more amino acid residues that will result in the destabilization of the loop region due to the targeted destruction of the hydrogen bond patterns created by these residues, and with the capsid protein containing such a modification giving the viral vector containing the capsid protein: a) increased transduction efficiency; and/or b) altered efficiency of tissue-specific transduction, resulting in increased transduction in one tissue compared to another tissue; compared to a viral vector involving a capsid protein that does not contain such a modification. The corresponding polynucleotide and parvovirus capsid are presented. A recombinant parvoviral vector for gene delivery is described, including: (a) the specified parvoviral capsid; and (b) a recombinant viral matrix containing: (i) a heterologous nucleic acid; and (ii) at least one inverted terminal repeat; with the recombinant viral matrix being encapsulated in the parvoviral capsid. In addition, a pharmaceutical composition containing the specified viral vector in a pharmacologically acceptable carrier is described. Methods of delivery of nucleic acid to the cell and to the individual using the specified viral vector or pharmaceutical composition are described. A method for producing a recombinant parvovirus particle is also presented.EFFECT: invention makes it possible to increase the transduction and expands the arsenal of means for delivering nucleic acids to the cell or to the individual.38 cl, 24 dwg, 11 tbl, 14 ex
Regadenoson 400mcg slow IV bolus to identify assess myocardial blood flow (MBF). Stratified by coronary calcium score of below 100 or greater than score of 100 for low and high risk individuals respectively.
Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
PROBLEM TO BE SOLVED: To obtain the subject new compound useful as an intermediate of a specific high-performance anionic surfactant being (S, S) body and excellent in biodegradability. SOLUTION: This compound is expressed by formula I [(n+1)=8-20; and (m)=1-8]. The compound of formula I is obtained by subjecting an (S, S) ethylenediamine tetraalkyl (a 1-8C alkyl) disuccinate and an acyl compound of formula II (X is a halogen, a hydroxyl or the like) to react in the presence of a basic catalyst (e.g. sodium hydroxide), e.g. using a mixed solvent of water/ acetone or a solvent such as toluene or xylene. Further, the compound of formula I is subjected to alkali hydrolysis to obtain a compound of formula III and the compound has low irritation to the skin, etc., with excellent feeling, and is useful as a detergent or an emulsifying agent of a cosmetic for hair.  Furthermore, the compound of formula I can be converted to an anionic surfactant containing two hydrophobic groups and two hydrophilic groups as a high- performance anionic surfactant after optionally subjecting to alkali hydrolysis and neutralization.
Herceptin starting 4 mg/kg intravenous (IV), then 2 mg/kg weekly for all other cycles neo-adjuvant chemotherapy and during FEC therapy for total 24 doses. Taxol 225 mg/m\^2 continuous IV over 24 hours each cycle; Fluorouracil 500 mg/m\^2 IV Days 1 at 3-4 week intervals; Cytoxan 500 mg/m\^2 IV on Day 1; Epirubicin 75 mg/m\^2 IV on Day 1. Four 21-day cycles.
Infants in Cohort 1 received a single VRC07-523LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
Renal Toxicity 

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy was usually followed by recovery to the pretreatment state. 

No information is available from controlled clinical studies regarding the use of naproxen and esomeprazole magnesium delayed-release tablets in patients with advanced renal disease. The renal effects of naproxen and esomeprazole magnesium delayed-release tablets may hasten the progression of renal dysfunction in patients with pre-existing renal disease. 

Correct volume status in dehydrated or hypovolemic patients prior to initiating naproxen and esomeprazole magnesium delayed-release tablets. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of naproxen and esomeprazole magnesium delayed-release tablets [see Drug Interactions (7)]. Avoid the use of naproxen and esomeprazole magnesium delayed-release tablets in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal failure. If naproxen and esomeprazole magnesium delayed-release tablets are used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

Hyperkalemia 

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
Low back pain occurs frequently and is one of the most costly health problems affecting industry and society. Prevention of low back pain is important both for the individual patient and from an economic perspective. Therefore, there are many measures available that claim to reduce low back pain and its recurrence. The most commonly used preventive strategies are fitness exercises, lumbar supports, education on back mechanics and lifting techniques, and ergonomic adjustments. However, their efficacy is still uncertain. The main objective of this study is to investigate the efficacy of two different design characteristics of lumbar support for low back pain prevention in hospital nurses. Investigators hope that those two types of lumbar support will reduce the incidence of low back pain and sick leave days. In addition, Investigators hypothesize that there are some differences on outcome measures between those two types of lumbar support. Enrolled subjects will be randomly assigned to one of the following three groups. The first group will wear an inelastic lumbar support for 6 months. The second group will wear an elastic lumbar support for 6 months. The third group will receive no intervention. After the completion of 6-month intervention, a further 6 months fellow-up will be added.
In patients randomized to receive the experimental therapy, transarterial embolization (TAE) treatments will be initiated within one week of randomization. Blunt embolization will be performed with LC beads with a maximum size of 700 µm. Microwave ablation (MWA) will be performed up to one month following randomization. The LC beads will be admixed with 8-15 mL of contrast and injected into the arterial branch at a rate of 1-2 mL/min. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request.
Participants will listen to the following auditory cues \~30 seconds apart You've got to walk faster than that. You're so slow! Why do you walk like that? Did you learn how to walk yesterday? You're doing terrible. Who walks like that? You have potential but you don't use it. You'll never amount to anything. You're not putting very much effort into this. This is the worst pace you've had yet.
This arm receives 15 hours per week of ESDM intervention from ESDM therapists. The parents benefit from a 20 hour parent training program delivered in the participating center.
Clinics randomized to the intervention arm will have participants complete a 6-month intervention period. Clinics will sign up eligible participants to receive automated SMS messages from the Dimagi CommCare platform during the participant's baseline study visit. Participants will have the option to tailor the message content based on their own preferences and will be able to select to receive messages in English or in Spanish, the time the messages are delivered, and frequency of messages. Clinic staff will enter this information in the Dimagi CommCare platform, and then test receipt of text messages by the participant before they complete this baseline visit.
Tumor-associated macrophages (TAMs), present within the tumor microenvironment (TME), strictly modulate tumor angiogenesis and lymphangiogenesis. Nevertheless, the associated signaling networks and candidate drug targets for these events remains to be elucidated. Given its antioxidative activities, we speculated that melatonin may reduce pyroptosis, and thereby modulate both angiogenesis and lymphangiogenesis. We revealed that a co-culture of A549 cells and THP-1 macrophages strongly enhanced expressions of the NLRP3 inflammasome axis members, and augmented angiogenesis and lymphangiogenesis. Next, we overexpressed NLRP3 in the A549 cells, and demonstrated that excess NLRP3 expression substantially upregulated VEGF and CXCL cytokine expressions, and enhanced lymphatic endothelial cells (LECs) tube formation. In contrast, NLRP3 inhibition produced the opposite effect. In addition, relative to controls, melatonin administration strongly inhibited the NLRP3 inflammasome axis, as well as angiogenesis and lymphangiogenesis in the co-culture system. Subsequent animal experiments using a Lewis Lung Carcinoma (LLC) subcutaneous tumor model in mice corroborate these findings. Melatonin treatment and NLRP3 knockdown significantly inhibit tumor growth and downregulate NLRP3 and IL-1β expression in tumor tissues. Furthermore, melatonin downregulates the expression of angiogenic and lymphangiogenic markers in tumor tissues. Taken together, the evidence suggested that a THP-1 macrophage and A549 cell co-culture stimulates angiogenesis and lymphangiogenesis via the NLRP3 axis. Melatonin protected against the TAMs- and NLRP3 axis-associated promotion of the aforementioned events in vitro and in vivo. Hence, melatonin is a promising candidate for managing for tumor-related angiogenesis and lymphangiogenesis in lung adenocarcinoma.
The study will include patients with HER2-positive breast cancer and 1- 3 distant metastatic lesions, all amenable for curative intervention. Patients will be stratified by prior therapy and ER expression. Given the basket-design of this trial other baskets for oligo-metastatic breast cancer can be added, such as but not limited to other breast cancer subtypes or with other promising drugs.

Baskets for de novo oligo-metastatic disease I. ER+/HER2+ II. ER-/HER2+ Baskets for oligo-metastatic disease after prior chemo/anti-HER2 therapy for primary disease III. ER+/HER2+ IV. ER-/HER2+
Flexible dose regimen of fesoterodine fumarate 4mg once daily. The dose can be increased to 8mg once daily after 4 weeks if clinically indicated. Subsequently the dose can be reduced to 4mg if clinically indicated.
Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily.
The conducted training by two groups, consisting of phasic contractions (3 sets of 10 repetitions of maximal contraction for two seconds to double or triple rest), endurance (two sets of six repetitions of sustained contractions of 6-10 seconds with the same rest time) and training effort, requesting the anticipated contraction of the abdominal pelvic floor coughing effort. We used the same protocol in the supine position, sitting and standing, as evolution of the patient. Both were treated 2 times per week, 20 minutes, totaling 8 sessions.
The waitlist control will continue usual care with no intervention for 6 months. To balance rigor with ethical considerations, they will receive the healthy food box deliveries after a 6 month waiting period.
The training program will last 12 weeks and consist of treadmill walking. The duration of the walking bouts (and pauses), and the speed of the belt will be adjusted as needed following the patients' progress. Music will be added as suited to boost motivation and support regular cadence. All training sessions will be supervised.
The invention discloses traditional Chinese medicine oral liquid for treating toothaches. The traditional Chinese medicine oral liquid is prepared from the following active pharmaceutical ingredients in parts by weight: 10-15 parts of bamboo leaves, 25-35 parts of realgar, 7-12 parts of baical skullcap root, 10-20 parts of oyster shell, 10-15 parts of cassia bark, 10-15 parts of common anemarrhena rhizome, 7-13 parts of Indian bread, 15-25 parts of honeysuckle, 6-12 parts of seville orange flower, 10-20 parts of paniculate swallowwort root, 3-8 parts of radix astragali, 6-12 parts of Chinese mahonia, 6-12 parts of Chinese lovage and 6-12 parts of fried great burdock achene. The traditional Chinese medicine decoction can be used for treating toothaches including toothaches caused by pulpitis, peripheral inflammation of tooth apexes, periodontal diseases and the like. The traditional Chinese medicine oral liquid is orally taken twice a day, about 10ml each time. Seven days is a course of treatment. Generally, the aches are obviously alleviated after a course of treatment. The aches basically disappear and redness and swelling of the gum disappear and are cured after two courses of treatment. After curing, the traditional Chinese medicine oral liquid can be continuously taken for one to three courses of treatment to consolidate the curative effects.
The invention discloses a traditional Chinese medicine composition for treating Crohn's disease and a preparation method and application thereof. The traditional Chinese medicine composition comprises, by weight, 8-15 parts of root, leaf and seed of Euonymus tobira Thunb., 22-30 parts of Herba Saginae Japonicae, 34-39 parts of polygala japonica and 5-12 parts of Passiflora wilsonii Hemsl.. The preparation method includes: mixing the root, leaf and seed of Euonymus tobira Thunb. with mixed liquid, drying, and grinding to obtain the powder of the root, leaf and seed of Euonymus tobira Thunb.; mixing the Herba Saginae Japonicae, the polygala japonica and the Passiflora wilsonii Hemsl., decocting with water, filtering, and concentrating under reduced pressure to obtain clear paste with the relative density being 1.05 under 45 DEG C; mixing the powder of the root, leaf and seed of Euonymus tobira Thunb. with the clear paste, and drying to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition has the advantages that the medicinal components of the traditional Chinese medicine composition are coordinated to achieve a good curative effect on the Crohn's disease, the total effective rate of the traditional Chinese medicine composition reaches 100%, and the traditional Chinese medicine composition is harmless to the heart, liver and kidney, definite and stable in curative effect, free of relapse and deterioration after cure, free of toxic and side effect, simple in preparation process, easy to prepare, low in cost and suitable for industrial production.
FIELD: molecular biology, biotechnology, medicine. SUBSTANCE: invention proposes a derivative that has five successively located immunoglobulin ICAM-1 domains and a cytoplasmatic domain ICAM-1 or transmembrane domain ICAM-1. DNA encoding a derivative of ICAM-1 is obtained by recombinant procedure. Derivative of ICAM-1 can be used as a highly effective antiinflammatory agent. EFFECT: enhanced effectiveness of a derivative. 3 dwg, 1 tbl, 1 ex
Alzheimer's disease (AD) is the most common cause of dementia. Despite intensive research efforts, there are currently no effective treatments to cure and prevent AD. There is growing evidence that dysregulation of iron homeostasis may contribute to the pathogenesis of AD. Given the important role of the transferrin receptor 1 (TfR1) in regulating iron distribution in the brain, as well as in the drug delivery, we investigated its expression in the brain cortex and isolated brain microvessels from female 8-month-old 5xFAD mice mimicking advanced stage of AD. Moreover, we explored the association between the TfR1 expression and the activation of the HIF-1 signaling pathway, as well as oxidative stress and inflammation in 5xFAD mice. Finally, we studied the impact of Aβ1-40 and Aβ1-42 on TfR1 expression in the brain endothelial cell line hCMEC/D3. In the present study, we revealed that an increase in TfR1 protein levels observed in the brain cortex of 5xFAD mice was associated with activation of the HIF-1 signaling pathway as well as accompanied by oxidative stress and inflammation. Interestingly, incubation of Aβ peptides in hCMEC/D3 cells did not affect the expression of TfR1, which supported our findings of unaltered TfR1 expression in the isolated brain microvessels in 5xFAD mice. In conclusion, the study provides important information about the expression of TfR1 in the 5xFAD mouse model and the potential role of HIF-1 signaling pathway in the regulation of TfR1 in AD, which could represent a promising strategy for the development of therapies for AD.